A simple pharmacokinetics subroutine for modeling double peak phenomenon

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 3, 2006, Pages 119-124

  Mirfazaelian, Ahmad ^a,c   Mahmoudian, Massoud ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Double peak; DRUG KNT; Oral; Pharmacokinetics; Single dose

Indexed keywords

PHENAZOPYRIDINE; PIROXICAM; RANITIDINE; TALINOLOL;

AKAIKE INFORMATION CRITERIA; ALGORITHM; ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; HUMAN; MATHEMATICAL COMPUTING; PREDICTION; RESIDUAL SUM OF SQUARES; STATISTICAL ANALYSIS;

ALGORITHMS; COMPUTER SIMULATION; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHENAZOPYRIDINE; PIROXICAM; PROPANOLAMINES; RANITIDINE; SOFTWARE;

EID: 33646382809     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.492     Document Type: Article

References (30)

1. Mostafavi SA, Foster RT. Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena. Int J Pharm 2003; 255: 81-86.
2. Oberle RL, Amidon GL. The influence of variable gastric-emptying and intestinal transit rates on the plasma-level curve of cimetidine - an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 1987; 15: 529-544.
3. Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic-renal-failure. J Cardiovasc Pharmacol 1995; 26: 394-400.
4. Polli JE, Bigora S, Piscitelli DA, Straughn AB, Young D. 'Pavlovian' food effect on the enterohepatic recirculation of piroxicam. Biopharm Drug Dispos 1996; 17: 635-641.
5. Zhou HW, Shen JQ, Lu M, Liang WQ, Lin W, Zhao WH. Pharmacokinetic analysis of enterohepatic circulation of piroxicam in rabbits. Acta Pharmacol Sinica 1992; 13: 180-182.
6. Boudinot FD, Ibrahim SS. High-performance liquid-chromatographic assay for piroxicam in human-plasma. J Chromatogr Biomed Appl 1988; 430: 424-428.
7. Richardson CJ, Blocka KLN, Ross SG, Verbeeck RK. Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther 1985; 37: 13-18.
8. Verbeeck RK, Richardson CJ, Blocka KLN. Clinical pharmacokinetics of piroxicam. J Rheumatol 1986; 13: 789-796.
9. Macek J, Vacha J. Rapid and sensitive method for determination of piroxicam in human-plasma by high-performance liquid-chromatography. J Chromatogr Biomed Appl 1987; 420: 445-449.
10. Yin OQP, Tomlinson B, Chow AHL, Chow MSS. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clin Pharmacokinet 2003; 42: 179-192.
11. Chow MSS, Yin QP, Tomlinson B, Chow AHL. Comparison of two pharmacokinetic models to describe the double-peak absorption profiles of ranitidine. Abstracts of 2001 American Society for Clinical Pharmacology & Therapeutics annual meeting. Clin Pharmacol Ther 2001; 69(2): 23 (Abstract PI-87).
12. Plusquellec Y, Efthymiopoulos C, Duthil P, Houin G. A pharmacokinetic model for multiple sites discontinuous gastrointestinal absorption. Med Engin Phys 1999; 21: 525-532.
13. Langguth P, Lee KM, Spahnlangguth H, Amidon GL. Variable gastric-emptying and discontinuities in drug absorption profiles - dependence of rates and extent of cimetidine absorption on motility phase and pH. Biopharm Drug Dispos 1994; 15: 719-746.
14. Mummaneni V, Dressman JB. Intestinal uptake of cimetidine and ranitidine in rats. Pharm Res 1994; 11: 1599-1604.
15. Suttle AB, Brouwer KLR. Bile-flow but not enterohepatic recirculation influences the pharmacokinetics of ranitidine in the rat. Drug Metab Dispos 1994; 22: 224-232.
16. Sadray S, Tajerzadeh H, Mohajer A, Mirfazaelian A, Rouini MR. Efficacy of urine samples in bioavailability study of ranitidine. Daru 2003; 11: 52-57.
17. Schaiquevich P, Niselman A, Rubio M. Comparison of two compartmental models for describing ranitidine's plasmatic profiles. Pharmacol Res 2002; 45: 399-405.
18. Weitschies W, Bernsdorf A, Giessmann T, et al. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 2005; 22: 728-735.
19. Sourgens H, Schmidt J, Derendorf H. Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters - results from the TALIP study. Int J Clin Pharmacol Ther 2003; 41: 22-29.
20. Wang YX, Roy A, Sun L, Lau CE. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 1999; 27: 855-859.
21. Shang EX, Xiang BR, Liu GY, Xie SF, Wei WY, Lu J. Determination of phenazopyridine in human plasma via LC-MS and subsequent development of a pharmacokinetic model. Anal Bioanal Chem 2005; 382: 216-222.
22. Pedersen PV, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 1980; 69: 394-398.
23. Beermann B. Value of plasma-digoxin estimation. Lancet 1973; 1: 375.
24. Parquet M, Metman EH, Raizman A, Rambaud JC, Berthaux N, Infante R. Bioavailability, gastrointestinal transit, solubilization and fecal excretion of ursodeoxycholic acid in man. Eur J Clin Invest 1985; 15: 171-178.
25. Holgate AM, Read NW. Effect of ileal infusion of intralipid on gastrointestinal transit, ileal flow-rate, and carbohydrate-absorption in humans after ingestion of a liquid meal. Gastroenterology 1985; 88: 1005-1011.
26. Lipka E, Lee ID, Langguth P, SpahnLangguth H, Mutschler E, Amidon GL. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 1995; 23: 267-286.
27. Zhou HH. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 2003; 43: 211-227.
28. Plusquellec Y, Campistron G, Staveris S, et al. A double-peak phenomenon in the pharmacokinetics of veralipride after oral-administration - a double-site model for drug absorption. J Pharmacokinet Biopharm 1987; 15: 225-239.
29. Mirfazaelian A, Mahmoudian M. A comprehensive computer programme for evaluation and teaching drug pharmacokinetics. Abstract of 12th Iranian Congress of Physiology and Pharmacology, 1995; 336 (Abstract P3-18).
30. Sehatpour H, Mahmoudian M, Gharavi V. Comparative bioavailability of two piroxicam formulations in relation to their dissolution. Abstract of 12th Iranian Congress of Physiology and Pharmacology, 1995; P3-33.